{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-019883","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.267035+00:00","generated_at":"2026-06-06T03:19:29.423141+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunome announces $138.1M cash estimate, commences public offering; updates pipeline and AL102 acquisition","bullets":["Preliminary cash, equivalents, and marketable securities of ~$138.1M as of Dec 31, 2023, subject to final close.","Underwritten public offering of common stock commenced; proceeds intended to fund pipeline and operations.","Signed asset purchase agreement with Ayala for AL102 (GSI) in desmoid tumors; expected close in late Q1 or early Q2 2024.","Pipeline: IND filings for IM-1021 (ROR1 ADC), IM-4320 (anti-IL-38), and FAP RLT all targeted for Q1 2025.","CEO Clay Siegall (former Seagen CEO) leads; management team includes former Morphimmune executives."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-019883","json":"https://secwatch.observer/filing/0001104659-24-019883.json","markdown":"https://secwatch.observer/filing/0001104659-24-019883.md","text":"https://secwatch.observer/filing/0001104659-24-019883.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924019883/0001104659-24-019883-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924019883/tm245878d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:19:29.423141+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}